Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Toward Precision Phenotyping of Multiple Sclerosis

Stuve Olaf; Bagnato Francesca; Longbrake Erin; Pitt David; Wesley Sarah; Pelletier Daniel; Topalli Ilir; Mao-Draayer Yang; Airas Laura M.; Lincoln Matthew R.; Kister Ilya; Lo Chih Hung; Boster Aaron; Gauthier Susan A.; Hickman Richard A.; Dutta Ranjan; Mansoor Mohammad; De Jager Philip Lawrence; Stathopoulos Panos; Riley Claire

Toward Precision Phenotyping of Multiple Sclerosis

Stuve Olaf
Bagnato Francesca
Longbrake Erin
Pitt David
Wesley Sarah
Pelletier Daniel
Topalli Ilir
Mao-Draayer Yang
Airas Laura M.
Lincoln Matthew R.
Kister Ilya
Lo Chih Hung
Boster Aaron
Gauthier Susan A.
Hickman Richard A.
Dutta Ranjan
Mansoor Mohammad
De Jager Philip Lawrence
Stathopoulos Panos
Riley Claire
Katso/Avaa
AirasEtAl2022TowardPrecisionPhenotypingOfMultipleSclerosis.pdf (439.9Kb)
Lataukset: 

NLM (Medline)
doi:10.1212/NXI.0000000000200025
URI
https://nn.neurology.org/content/9/6/e200025
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2022102463112
Tiivistelmä

The classification of multiple sclerosis (MS) has been established by Lublin in 1996 and revised in 2013. The revision includes clinically isolated syndrome, relapsing-remitting, primary progressive and secondary progressive MS, and has added activity (i.e., formation of white matter lesions or clinical relapses) as a qualifier. This allows for the distinction between active and nonactive progression, which has been shown to be of clinical importance. We propose that a logical extension of this classification is the incorporation of additional key pathological processes, such as chronic perilesional inflammation, neuroaxonal degeneration, and remyelination. This will distinguish MS phenotypes that may present as clinically identical but are driven by different combinations of pathological processes. A more precise description of MS phenotypes will improve prognostication and personalized care as well as clinical trial design. Thus, our proposal provides an expanded framework for conceptualizing MS and for guiding development of biomarkers for monitoring activity along the main pathological axes in MS.

Kokoelmat
  • Rinnakkaistallenteet [19207]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste